Apigenin inhibits tumorigenesis in cisplatin-resistant CRC cells both in vitro and in vivo by inducing autophagy, and programmed cell death and targeting the mTOR/PI3K/Akt signaling pathway (Chen et al., 2019). The gene discussed is AKT1; the disease is colorectal carcinoma.